Study S001285

A Parallel, Double-blinded, Randomized, 6 Months, Two Arms Study With Lifestyle Intervention and Bydureon® or Lifestyle Intervention and Placebo in Adolescents With Obesity to Explore Differences With Regard to Change in BMI SDS

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02794402
Acronym: Combat-JUDO
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 44
Start: 2015-09
Primary completion: 2016-09
Lead sponsor: Uppsala University
Conditions: Obesity
Interventions: DRUG:Exenatide; BEHAVIORAL:Placebo
Results posted: FALSE
Secondary identifiers: NIH:2015

Registered primary outcomes

BMI SDS (Body Mass Index Standard Deviation Score) [6 months]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0043652	Cardiovascular Risk Factors and Aspects of GLP-1 Treatment in Pediatric Obesity Stenlid, Rasmus, KTH Publication Database DiVA (KTH Royal Institute of Technology)	2025	Randomized trial		cites ClinicalTrials.gov:NCT02794402
R0010847	Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control. Stenlid R, Frontiers in endocrinology	2023	Randomized trial	PMID 38027106 DOI	cites ClinicalTrials.gov:NCT02794402; registry reference DERIVED:38027106